Barclays
FENC icon

Barclays’s Fennec Pharmaceuticals FENC Stock Holding History

Barclays’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.6K Sell
6,273
-30,324
-83% -$234K ﹤0.01% 4403
2025
Q4 		$282K Buy
36,597
+3,559
+11% +$29.2K ﹤0.01% 4150
2025
Q3 		$309K Sell
33,038
-6,967
-17% -$60.3K ﹤0.01% 4076
2025
Q2 		$332K Buy
40,005
+15,704
+65% +$107K ﹤0.01% 3990
2025
Q1 		$148K Sell
24,301
-11,371
-32% -$73K ﹤0.01% 4204
2024
Q4 		$225K Buy
35,672
+4,353
+14% +$22.3K ﹤0.01% 4253
2024
Q3 		$157K Buy
31,319
+22,951
+274% +$133K ﹤0.01% 4416
2024
Q2 		$51.1K Sell
8,368
-4,508
-35% -$37.4K ﹤0.01% 4206
2024
Q1 		$143K Sell
12,876
-12,199
-49% -$122K ﹤0.01% 4287
2023
Q4 		$281K Buy
25,075
+21,615
+625% +$179K ﹤0.01% 4259
2023
Q3 		$26K Sell
3,460
-175
-5% -$1.42K ﹤0.01% 4107
2023
Q2 		$32.1K Sell
3,635
-6,062
-63% -$50.4K ﹤0.01% 4016
2023
Q1 		$80.7K Buy
9,697
+437
+5% +$4.05K ﹤0.01% 4282
2022
Q4 		$88.9K Buy
+9,260
New +$81.9K ﹤0.01% 4296
2021
Q4 		– Sell
-2,648
Closed -$25K – 4301
2021
Q3 		$25K Sell
2,648
-346
-12% -$2.6K ﹤0.01% 4332
2021
Q2 		$21K Sell
2,994
-15,200
-84% -$101K ﹤0.01% 4475
2021
Q1 		$113K Buy
18,194
+11,170
+159% +$84.1K ﹤0.01% 3950
2020
Q4 		$53K Sell
7,024
-2,779
-28% -$21.2K ﹤0.01% 4377
2020
Q3 		$60K Sell
9,803
-2,162
-18% -$15.2K ﹤0.01% 4502
2020
Q2 		$100K Buy
+11,965
New +$89K ﹤0.01% 4514
2019
Q3 		– Sell
-543
Closed -$2K – 6822
2019
Q2 		$2K Sell
543
-2,873
-84% -$12.2K ﹤0.01% 6799
2019
Q1 		$17K Buy
+3,416
New +$22.5K ﹤0.01% 6407
2018
Q4 		– Sell
-4,631
Closed -$38K – 7048
2018
Q3 		$38K Buy
4,631
+3,801
+458% +$35.3K ﹤0.01% 6216
2018
Q2 		$8K Buy
+830
New +$9.84K ﹤0.01% 6610

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Barclays's FENC Position: Q1 2026 in Review

Barclays reduced its Fennec Pharmaceuticals (FENC) stake by 83% in Q1 2026, selling an estimated $234K and leaving 6,273 shares worth $38.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4403.

Barclays first reported a position in FENC in Q2 2018 and has held it in 24 quarters since. The position peaked at $332K in Q2 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Barclays held 6,273 shares of Fennec Pharmaceuticals worth $38.6K as of Q1 2026.
  • Barclays sold 30,324 Fennec Pharmaceuticals shares in Q1 2026, an estimated $234K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4403 holding.
  • Barclays first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 24 quarters since.
  • Barclays's Fennec Pharmaceuticals position peaked at $332K in Q2 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.